Chairman Rick Scott joins effort at White House to strengthen America’s Drug Supply Chain and advance CLEAR LABELS act

Venezuela RED Informativa.us
In case you missed it, Chairman Rick Scott joined a roundtable at the White House alongside senior Trump administration officials and industry leaders to highlight the importance of strengthening U.S. drug manufacturing, supporting American jobs, and keeping our families safe.
During the roundtable, Chairman Scott emphasized the urgent need to end America’s dangerous overreliance on foreign drug manufacturers in India and Communist China to ensure the medicines American patients take every day are safe and readily available, while also prioritizing the creation of American jobs.
Chairman Scott also shared the U.S. Senate Special Committee on Aging’s work to increase transparency and accountability across America’s drug and medical supply chain, including his bipartisan investigative report and CLEAR LABELS Act, which would require country-of-origin labeling for prescription medicines and their ingredients, ensuring Americans know exactly where the drugs in their medicine cabinets are produced.
See below to read more about Chairman Scott’s bipartisan work on the U.S. Senate Special Committee on Aging:
03/25/26: Chairman Scott Applauds CMS Advanced Notice of Proposed Rulemaking to Strengthen America’s Medical Supply Chains
03/13/26: ICYMI: Chairman Scott, Ranking Member Gillibrand Highlight CLEAR LABELS Act in ABC News Interview on Securing U.S. Drug Supply Chain
03/11/26: Chairman Scott Exposes Communist China’s Dangerous Grip on America’s Medicine Supply; Highlights CLEAR LABELS Act to Increase Transparency
03/05/26: Chairman Scott’s CLEAR LABELS Act Garners Bicameral Support with Rep. McCormick in the U.S. House
03/04/26: Chairman Scott, Ranking Member Gillibrand Press America’s Pharmacies on U.S. Drug Supply Chain and Country-of-Origin Labeling for Foreign-Made Drugs
02/19/26: Chairman Scott Sends Letter to Secretary Hegseth on Securing Generic Drug Supply for Service Members and Veterans
02/05/26: Chairman Scott, Ranking Member Gillibrand Introduce CLEAR LABELS Act to Protect American Patients Through Drug Origin Transparency and Stronger Supply Chain Oversight
01/29/26: Chairman Scott Calls for Transparency of Foreign-Made Generic Drugs, Announces CLEAR LABELS Act to Require Country-of-Origin Labeling
11/20/25: Chairman Scott, Ranking Member Gillibrand Send Letter to VA Secretary on Protecting Veterans’ Pharmaceutical Supply Chains
11/19/25: Chairman Scott Leads Aging Hearing on Navigating Path to Restoring U.S. Leadership in Essential Drug Manufacturing
11/11/25: Chairman Scott, Ranking Member Gillibrand Send Letter to Major U.S. Pharmacies on Foreign Drug Supply Chain Vulnerabilities
10/30/25: Chairman Scott, Ranking Member Gillibrand Send Letter to Pharmaceutical Distributor Executives on Regulatory Oversight of Foreign-Manufactured Generic Drugs
10/29/25: Chairman Scott, Ranking Member Gillibrand Send Letter to Group Purchasing Organization Executives on Regulatory Oversight of Foreign-Manufactured Generic Drugs
10/24/25: Chairman Scott, Ranking Member Gillibrand Pen Letter to HHS on Dangers of Overreliance on Foreign-Manufactured Generic Drugs and Request Information on HHS’s Efforts to Combat Vulnerabilities
10/20/25: Chairman Scott, Ranking Member Gillibrand Release Investigative Report Exposing America’s Dangerous Overreliance on Foreign-Made Generic Drugs, Proposing Bipartisan Policy Recommendations
10/08/25: Chairman Scott Leads Aging Committee Hearing on Closing Deadly Generic Drug Loopholes and Rebuilding America’s Essential Medicine Supply
09/18/25: Chairman Scott, Ranking Member Gillibrand Pen Bipartisan Letter to FDA Commissioner on Oversight and Safety of Foreign-Manufactured Generic Drugs, Requests Answers on Ties to Forced Labor in China
09/17/25: Chairman Scott: U.S. Overdependence on Foreign-Manufactured Generic Drugs Threatens Lives of America’s Seniors & National Security
04/01/25: Chairman Scott, Sens. Moody and Justice Ask FDA to Prioritize Foreign & Domestic Drug Quality and Protect Seniors



